{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:09:56Z","timestamp":1791295796567,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T00:00:00Z","timestamp":1507680000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s00432-017-2529-9","type":"journal-article","created":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T12:58:10Z","timestamp":1507726690000},"page":"629-635","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Survival benefit of mantle cell lymphoma patients enrolled in clinical trials; a joint study from the LYSA group and French cancer registries"],"prefix":"10.1007","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6006-1169","authenticated-orcid":false,"given":"Alix","family":"Augustin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9my","family":"Gressin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Bertaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Monnereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Woronoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Tr\u00e9tarre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Delafosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Troussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Maynadi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,11]]},"reference":[{"key":"2529_CR1","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.3109\/10428194.2011.587560","volume":"52","author":"A Abrahamsson","year":"2011","unstructured":"Abrahamsson A, Dahle N, Jerkeman M (2011) Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry. Leuk Lymphoma 52:1929\u20131935. doi: 10.3109\/10428194.2011.587560","journal-title":"Leuk Lymphoma"},{"key":"2529_CR2","first-page":"401","volume":"38","author":"NS Andersen","year":"2002","unstructured":"Andersen NS, Jensen MK, de Nully Brown P, Geisler CH (2002) A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors. Eur J Cancer Oxf Engl 1990 38:401\u2013408","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"2529_CR3","doi-asserted-by":"publisher","unstructured":"Cheah CY, Seymour JF, Wang ML (2016) Mantle cell lymphoma. J Clin Oncol, p. JCO635904. doi: 10.1200\/JCO.2015.63.5904","DOI":"10.1200\/JCO.2015.63.5904"},{"key":"2529_CR4","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3324\/haematol.2013.087601","volume":"98","author":"A Cherubini","year":"2013","unstructured":"Cherubini A, Pierri F, Gasperini B et al (2013) Are ongoing trials on hematologic malignancies still excluding older subjects? Haematologica 98:997\u20131000. doi: 10.3324\/haematol.2013.087601","journal-title":"Haematologica"},{"key":"2529_CR5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","volume":"121","author":"R Delarue","year":"2013","unstructured":"Delarue R, Haioun C, Ribrag V et al (2013) CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. Blood 121:48\u201353. doi: 10.1182\/blood-2011-09-370320","journal-title":"Blood"},{"key":"2529_CR6","doi-asserted-by":"publisher","unstructured":"Dreyling M, Hiddemann W, European MCL Network (2009) Current treatment standards and emerging strategies in mantle cell lymphoma. Hematol Educ Program Am Soc Hematol Am Soc Hematol Educ Program, pp 542\u2013551. doi: 10.1182\/asheducation-2009.1.542","DOI":"10.1182\/asheducation-2009.1.542"},{"key":"2529_CR7","doi-asserted-by":"publisher","unstructured":"Dreyling M, Geisler C, Hermine O, et al (2014) Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25: iii83\u2013iii92. doi: 10.1093\/annonc\/mdu264","DOI":"10.1093\/annonc\/mdu264"},{"key":"2529_CR8","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.dld.2015.05.017","volume":"47","author":"M Fr\u00e9rot","year":"2015","unstructured":"Fr\u00e9rot M, Jooste V, Binquet C et al (2015) Factors influencing inclusion in digestive cancer clinical trials: a population-based study. Dig Liver Dis 47:891\u2013896. doi: 10.1016\/j.dld.2015.05.017","journal-title":"Dig Liver Dis"},{"key":"2529_CR9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1182\/blood.V128.22.145.145","volume":"128","author":"SL Gouill","year":"2016","unstructured":"Gouill SL, Thieblemont C, Oberic L et al (2016) Rituximab maintenance after autologous stem cell transplantation prolongs survival in younger patients with mantle cell lymphoma: final Results of the randomized phase 3 LyMa trial of the Lysa\/Goelams Group. Blood 128:145","journal-title":"Blood"},{"key":"2529_CR10","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/biom.12477","volume":"72","author":"N Graff\u00e9o","year":"2016","unstructured":"Graff\u00e9o N, Castell F, Belot A, Giorgi R (2016) A log-rank-type test to compare net survival distributions. Biometrics 72:760\u2013769. doi: 10.1111\/biom.12477","journal-title":"Biometrics"},{"key":"2529_CR11","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.3324\/haematol.2009.011759","volume":"95","author":"R Gressin","year":"2010","unstructured":"Gressin R, Caulet-Maugendre S, Deconinck E et al (2010) Evaluation of the (R)VAD\u00a0+\u00a0C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. Haematologica 95:1350\u20131357. doi: 10.3324\/haematol.2009.011759","journal-title":"Haematologica"},{"key":"2529_CR12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/hon.2437_131","volume":"35","author":"R Gressin","year":"2017","unstructured":"Gressin R, Daguindau N, Tempescul A et al (2017) First line treatment by the RIBVD regimen elicits high clinical and molecular response rates and prolonged survival in elderly MCL patients; final results of a LYSA group trial. Hematol Oncol 35:141\u2013142. doi: 10.1002\/hon.2437_131","journal-title":"Hematol Oncol"},{"issue":"10","key":"2529_CR13","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1634\/theoncologist.2014-0093","volume":"19","author":"ME Hamaker","year":"2014","unstructured":"Hamaker ME, Stauder R, van Munster BC (2014) Exclusion of older patients from ongoing clinical trials for hematological malignancies: an evaluation of the National Institutes of Health Clinical Trial Registry. Oncologist 19(10):1069\u20131075. doi: 10.1634\/theoncologist.2014-0093","journal-title":"Oncologist"},{"key":"2529_CR14","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","volume":"17","author":"NL Harris","year":"1999","unstructured":"Harris NL, Jaffe ES, Diebold J et al (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol Off J Am Soc Clin Oncol 17:3835\u20133849","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2529_CR15","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"O Hermine","year":"2016","unstructured":"Hermine O, Hoster E, Walewski J et al (2016) Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65\u00a0years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. The Lancet 388:565\u2013575. doi: 10.1016\/S0140-6736(16)00739-X","journal-title":"The Lancet"},{"key":"2529_CR16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/DCR.0b013e318197d13c","volume":"52","author":"P Kalata","year":"2009","unstructured":"Kalata P, Martus P, Zettl H et al (2009) Differences between clinical trial participants and patients in a population-based registry: the German Rectal Cancer Study vs. the Rostock Cancer Registry. Dis Colon Rectum 52:425\u2013437. doi: 10.1007\/DCR.0b013e318197d13c","journal-title":"Dis Colon Rectum"},{"key":"2529_CR17","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1179\/102453310X12719010991623","volume":"15","author":"J Lemieux","year":"2010","unstructured":"Lemieux J, Amireault C, Camden S, Poulin J (2010) Evaluation of factors associated with recruitment in hematological clinical trials: a retrospective cohort study. Hematol Amst Neth 15:373\u2013377. doi: 10.1179\/102453310X12719010991623","journal-title":"Hematol Amst Neth"},{"key":"2529_CR18","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"G Lenz","year":"2005","unstructured":"Lenz G, Dreyling M, Hoster E et al (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol Off J Am Soc Clin Oncol 23:1984\u20131992. doi: 10.1200\/JCO.2005.08.133","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2529_CR19","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s00277-014-2049-5","volume":"93","author":"C Leux","year":"2014","unstructured":"Leux C, Maynadi\u00e9 M, Troussard X et al (2014) Mantle cell lymphoma epidemiology: a population-based study in France. Ann Hematol 93:1327\u20131333. doi: 10.1007\/s00277-014-2049-5","journal-title":"Ann Hematol"},{"key":"2529_CR20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1159\/000445410","volume":"39","author":"G Logroscino","year":"2016","unstructured":"Logroscino G, Capozzo R, Tortelli R, Marin B (2016) Current issues in randomized clinical trials of neurodegenerative disorders at enrolment and reporting: diagnosis, recruitment, representativeness of patients, ethnicity, and quality of reporting. Front Neurol Neurosci 39:24\u201336. doi: 10.1159\/000445410","journal-title":"Front Neurol Neurosci"},{"key":"2529_CR21","unstructured":"Monnereau A, Remontet L, Maynadi\u00e9 M, et al (2013) Estimation nationale de l\u2019incidence des cancers en France entre 1980 et 2012. Institut de veille sanitaire"},{"key":"2529_CR22","doi-asserted-by":"publisher","first-page":"5486","DOI":"10.1002\/sim.3064","volume":"26","author":"CP Nelson","year":"2007","unstructured":"Nelson CP, Lambert PC, Squire IB, Jones DR (2007) Flexible parametric models for relative survival, with application in coronary heart disease. Stat Med 26:5486\u20135498. doi: 10.1002\/sim.3064","journal-title":"Stat Med"},{"key":"2529_CR23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1541-0420.2011.01640.x","volume":"68","author":"MP Perme","year":"2012","unstructured":"Perme MP, Stare J, Est\u00e8ve J (2012) On estimation in relative survival. Biometrics 68:113\u2013120. doi: 10.1111\/j.1541-0420.2011.01640.x","journal-title":"Biometrics"},{"key":"2529_CR24","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/j.compbiomed.2007.04.010","volume":"37","author":"M Pohar","year":"2007","unstructured":"Pohar M, Stare J (2007) Making relative survival analysis relatively easy. Comput Biol Med 37:1741\u20131749. doi: 10.1016\/j.compbiomed.2007.04.010","journal-title":"Comput Biol Med"},{"key":"2529_CR25","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1002\/sim.1203","volume":"21","author":"P Royston","year":"2002","unstructured":"Royston P, Parmar MKB (2002) Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med 21:2175\u20132197. doi: 10.1002\/sim.1203","journal-title":"Stat Med"},{"key":"2529_CR26","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s10552-008-9201-2","volume":"19","author":"J Sepp\u00e4nen","year":"2008","unstructured":"Sepp\u00e4nen J, Hein\u00e4vaara S, Holli K, Hakulinen T (2008) Comparison of cancer registry and clinical data as predictors for breast cancer survival. Cancer Causes Control 19:1299\u20131304. doi: 10.1007\/s10552-008-9201-2","journal-title":"Cancer Causes Control"},{"key":"2529_CR27","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1093\/annonc\/mdq214","volume":"21","author":"C Tersch\u00fcren","year":"2010","unstructured":"Tersch\u00fcren C, Gierer S, Brillant C et al (2010) Are patients with Hodgkin lymphoma and high-grade non-Hodgkin lymphoma in clinical therapy optimization protocols representative of these groups of patients in Germany? Ann Oncol Off J Eur Soc Med Oncol ESMO 21:2045\u20132051. doi: 10.1093\/annonc\/mdq214","journal-title":"Ann Oncol Off J Eur Soc Med Oncol ESMO"},{"key":"2529_CR28","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1200\/JCO.2005.00.141","volume":"23","author":"CA Townsley","year":"2005","unstructured":"Townsley CA, Selby R, Siu LL (2005) Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 23:3112\u20133124. doi: 10.1200\/JCO.2005.00.141","journal-title":"J Clin Oncol"},{"key":"2529_CR29","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/cncr.23608","volume":"113","author":"Y Zhou","year":"2008","unstructured":"Zhou Y, Wang H, Fang W et al (2008) Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 113:791\u2013798. doi: 10.1002\/cncr.23608","journal-title":"Cancer"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-017-2529-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2529-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2529-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T15:07:59Z","timestamp":1603120079000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-017-2529-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,11]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["2529"],"URL":"https:\/\/doi.org\/10.1007\/s00432-017-2529-9","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,11]]}}}